Duda Lab
Mohamed YI, Duda DG, Awiwi MO, Lee SS, Altameemi L, Xiao L, Morris JS, Wolff RA, Elsayes KM, Hatia RI, Qayyum A, Chamseddine SM, Rashid A, Yao JC, Mahvash A, Hassan MM, Amin HM, Kaseb AO
Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients.
Oncotarget. 2022;13:1314-1321 - PMID: 36473155 - PMCID: PMC9726202 - DOI: 10.18632/oncotarget.28322
Sasaki T, Shigeta K, Kitahara S, Suzuki Y, Matsui S, Seishima R, Okabayashi K, Duda DG, Kitagawa Y
Inhibition of STAT3 Promotes Effector T Cell Infiltration But also Immunosuppression in the HCC Tumor Microenvironment.
Anticancer Res. 2022;42(11):5205-5215 - PMID: 36288859 - DOI: 10.21873/anticanres.16027
Nagalo BM, Zhou Y, Loeuillard EJ, Dumbauld C, Barro O, Elliott NM, Baker AT, Arora M, Bogenberger JM, Meurice N, Petit J, Uson Junior PLS, Aslam F, Raupach E, Gabere M, Basnakian A, Simoes CC, Cannon MJ, Post SR, Buetow K, Chamcheu JC, Barrett MT, Duda DG, Jacobs B, Vile R, Barry MA, Roberts LR, Ilyas S, Borad MJ
Characterization of Morreton Virus (MORV) as a Novel Oncolytic Virotherapy Platform for Liver Cancers.
Hepatology. 2022;77(6):1943-1957 - PMID: 36052732 - DOI: 10.1002/hep.32769
Dima SO, Dumitraşcu T, Popescu I, Duda DG
Using Molecular Subtyping of Pancreatic Ductal Adenocarcinoma for Multimodal Treatment Selection in Resectable Disease.
Chirurgia (Bucur). 2022;117(4):407-414 - PMID: 36049097 - DOI: 10.21614/chirurgia.2772
Munoz NM, Dupuis C, Williams M, Dixon K, McWatters A, Zhang J, Pavuluri S, Rao A, Duda DG, Kaseb A, Sheth RA
Immune modulation by molecularly targeted photothermal ablation in a mouse model of advanced hepatocellular carcinoma and cirrhosis.
Sci Rep. 2022;12(1):14449 - PMID: 36002545 - PMCID: PMC9402568 - DOI: 10.1038/s41598-022-15948-3
How J, Ren S, Lombardi-Story J, Bergeron M, Foster J, Amrein PC, Brunner AM, Fathi AT, Hock H, Khachatryan A, Kikuchi H, Ng MR, Moran J, Narayan R, Neuberg D, Ramos A, Som T, Vartanian M, Chen YB, Duda DG, Hobbs GS
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies.
EJHaem. 2022;3(2):434-442 - PMID: 35846042 - PMCID: PMC9175677 - DOI: 10.1002/jha2.408
Saulnier Sholler G, Duda DG, Bergendahl G, Ebb D, Snuderl M, Laetsch TW, Michlitsch J, Hanson D, Isakoff MS, Bielamowicz K, Kraveka JM, Ferguson W, Carmeliet P, De Deene A, Gijsen L, Jain RK
A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma.
Clin Cancer Res. 2022;28(18):3950-3957 - PMID: 35833850 - PMCID: PMC9481695 - DOI: 10.1158/1078-0432.CCR-22-1169
Morita S, Duda DG
Refining genetic and molecular classifications to facilitate breakthrough treatments in intrahepatic cholangiocarcinoma: are we there yet?
Gut. 2022;72(4):608-610 - PMID: 35772925 - PMCID: PMC10435277 - DOI: 10.1136/gutjnl-2022-327782
Martin JD, Lanning RM, Chauhan VP, Martin MR, Mousa AS, Kamoun WS, Han HS, Lee H, Stylianopoulos T, Bawendi MG, Duda DG, Brown EB, Padera TP, Fukumura D, Jain RK
Multiphoton phosphorescence quenching microscopy reveals kinetics of tumor oxygenation during anti-angiogenesis and angiotensin signaling inhibition.
Clin Cancer Res. 2022;28(14):3076-3090 - PMID: 35584239 - PMCID: PMC9355624 - DOI: 10.1158/1078-0432.CCR-22-0486
Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang Y, Yi P, Huang Z, Peng F, Hu X, Fan X
VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
J Transl Med. 2022;20(1):212 - PMID: 35562734 - PMCID: PMC9102726 - DOI: 10.1186/s12967-022-03416-5
Kikuchi H, Matsui A, Morita S, Amoozgar Z, Inoue K, Ruan Z, Staiculescu D, Wong JS, Huang P, Yau T, Jain RK, Duda DG
Increased CD8+ T-Cell Infiltration and Efficacy for Multikinase Inhibitors after PD-1 Blockade in Hepatocellular Carcinoma.
J Natl Cancer Inst. 2022;114(9):1301-1305 - PMID: 35288743 - PMCID: PMC9468280 - DOI: 10.1093/jnci/djac051
Hauth F, Roberts HJ, Hong TS, Duda DG
Leveraging Blood-Based Diagnostics to Predict Tumor Biology and Extend the Application and Personalization of Radiotherapy in Liver Cancers.
Int J Mol Sci. 2022;23(4):ePub - PMID: 35216045 - PMCID: PMC8879105 - DOI: 10.3390/ijms23041926
Xiao Y, Chen J, Zhou H, Zeng X, Ruan Z, Pu Z, Jiang X, Matsui A, Zhu L, Amoozgar Z, Chen DS, Han X, Duda DG, Shi J
Combining p53 mRNA nanotherapy with immune checkpoint blockade reprograms the immune microenvironment for effective cancer therapy.
Nat Commun. 2022;13(1):758 - PMID: 35140208 - PMCID: PMC8828745 - DOI: 10.1038/s41467-022-28279-8
13